Literature DB >> 12797349

Crohn's disease and IL-10 therapy: promise regained.

Willem J S de Villiers1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2003        PMID： 12797349     DOI： 10.1097/00054725-200305000-00012

Source DB:  PubMed          Journal:  Inflamm Bowel Dis        ISSN： 1078-0998            Impact factor:   5.325


× No keyword cloud information.
  4 in total

1.  Escherichia coli Nissle 1917 distinctively modulates T-cell cycling and expansion via toll-like receptor 2 signaling.

Authors:  Andreas Sturm; Klaus Rilling; Daniel C Baumgart; Konstantinos Gargas; Tay Abou-Ghazalé; Bärbel Raupach; Jana Eckert; Ralf R Schumann; Corinne Enders; Ulrich Sonnenborn; Bertram Wiedenmann; Axel U Dignass
Journal:  Infect Immun       Date:  2005-03       Impact factor: 3.441

2.  Interleukin-10 inhibits the in vivo and in vitro adverse effects of TNF-alpha on the endothelium of murine aorta.

Authors:  Saiprasad M Zemse; Chin Wei Chiao; Rob H P Hilgers; R Clinton Webb
Journal:  Am J Physiol Heart Circ Physiol       Date:  2010-07-16       Impact factor: 4.733

Review 3.  Recombinant human interleukin 10 for induction of remission in Crohn's disease.

Authors:  Felicia Elena Buruiana; Ivan Solà; Pablo Alonso-Coello
Journal:  Cochrane Database Syst Rev       Date:  2010-11-10

4.  Novel anti-inflammatory functions for endothelial and myeloid cyclooxygenase-2 in a new mouse model of Crohn's disease.

Authors:  Junji Watanabe; James A Lin; Ajay J Narasimha; Ani Shahbazian; Tomo-O Ishikawa; Martin G Martin; Harvey R Herschman; Srinivasa T Reddy
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2010-03-18       Impact factor: 4.052
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.